Detalhe da pesquisa
1.
Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease.
Clin Gastroenterol Hepatol
; 13(2): 316-21, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25038374
2.
Adalimumab induces deep remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 12(3): 414-22.e5, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23856361
3.
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
J Am Acad Dermatol
; 66(2): e67-76, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21616560
4.
Risks of developing psychiatric disorders in pediatric patients with psoriasis.
J Am Acad Dermatol
; 67(4): 651-7.e1-2, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22243764
5.
Increased risks of developing anxiety and depression in young patients with Crohn's disease.
Am J Gastroenterol
; 106(9): 1670-7, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21537359
6.
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
Clin Drug Investig
; 31(1): 51-60, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20932070
7.
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
J Am Acad Dermatol
; 63(6): 1011-8, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20933301
8.
Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
Dermatology
; 220(1): 1-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19940437
9.
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.
Dermatology
; 220(2): 128-37, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130383
10.
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Am J Gastroenterol
; 104(5): 1170-9, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19352339
11.
Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
Pharmacoeconomics
; 27(7): 609-21, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19663531
12.
Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
Value Health
; 11(5): 820-9, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18489509
13.
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
J Crohns Colitis
; 7(1): 34-43, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22480772
14.
Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Inflamm Bowel Dis
; 18(11): 2043-55, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22241679
15.
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
Inflamm Bowel Dis
; 17(1): 127-40, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20848523
16.
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Am J Clin Dermatol
; 12(1): 51-62, 2011 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21110526
17.
Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmacies.
Adv Ther
; 27(8): 523-32, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20652656
18.
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.
Pharmacoeconomics
; 28(10): 935-45, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20831302
19.
Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Adv Ther
; 26(10): 936-46, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19838649
20.
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Eur J Gastroenterol Hepatol
; 21(11): 1302-9, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19465858